Read by QxMD icon Read

breast IVF infertility

Jacek Gronwald, Karen Glass, Barry Rosen, Beth Karlan, Nadine Tung, Susan L Neuhausen, Pal Moller, Peter Ainsworth, Ping Sun, Steven A Narod, Jan Lubinski, Joanne Kotsopoulos
OBJECTIVE: To evaluate the relationship between use of fertility medication (i.e., selective estrogen receptor [ER] modulator, gonadotropin, or other) or infertility treatment (i.e., IVF or IUI) and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. DESIGN: A matched case-control study of 941 pairs of BRCA1 or BRCA2 mutation carriers with and without a diagnosis of ovarian cancer. SETTING: Genetic clinics. PATIENT(S): Detailed information regarding treatment of infertility was collected from a routinely administered questionnaire...
March 2016: Fertility and Sterility
Nicolas Chevalier, Françoise Paris, Sylvie Fontana, Jérôme Delotte, Laura Gaspari, Patricia Ferrari, Charles Sultan, Patrick Fénichel
BACKGROUND: McCune-Albright syndrome (MAS), due to a somatic mutation of the GNAS1 gene, begins usually in girls with peripheral precocious puberty. Ovarian autonomy may persist in adulthood with acyclic hyperestrogenemia, infertility, and a potential risk of estrogen-dependent cancer. CASE: A 22-year-old woman, with MAS, was referred for infertility with left macropolycystic ovary, hyperestrogenemia, and chronic anovulation unsuccessfully treated by controlled hyperstimulation...
December 2015: Journal of Pediatric and Adolescent Gynecology
O Goldrat, C Gervy, Y Englert, A Delbaere, I Demeestere
STUDY QUESTION: Are progesterone levels after letrozole-associated controlled ovarian stimulation (COS) for fertility preservation in breast cancer patients, lower than after standard in vitro fertilization (IVF) cycles? SUMMARY ANSWER: During the luteal phase of letrozole-associated COS cycles (triggered with human chorionic gonadotrophin (hCG)) progesterone levels are similarly elevated to those obtained after standard COS without letrozole. WHAT IS KNOWN ALREADY: Current fertility preservation strategies for breast cancer patients include association of COS with the aromatase inhibitor letrozole to harvest several mature oocytes while maintaining low estradiol levels...
September 2015: Human Reproduction
Kutluk Oktay, Volkan Turan, Giuliano Bedoschi, Fernanda S Pacheco, Fred Moy
PURPOSE: We have previously reported an approach to ovarian stimulation for the purpose of fertility preservation (FP) in women with breast cancer via embryo freezing with the concurrent use of letrozole. The aim of this study was to provide the pregnancy and FP outcomes when embryos generated with the same protocol are used. PATIENTS AND METHODS: In all, 131 women with stage ≤ 3 breast cancer underwent ovarian stimulation and received concurrent letrozole 5 mg per day before receiving adjuvant chemotherapy and cryopreserving embryos...
August 1, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Aya Shohat-Tal, Aritro Sen, David H Barad, Vitaly Kushnir, Norbert Gleicher
Hypoandrogenism in women with low functional ovarian reserve (LFOR, defined as an abnormally low number of small growing follicles) adversely affects fertility. The androgen precursor dehydroepiandrosterone (DHEA) is increasingly used to supplement treatment protocols in women with LFOR undergoing in vitro fertilization. Due to differences in androgen metabolism, however, responses to DHEA supplementation vary between patients. In addition to overall declines in steroidogenic capacity with advancing age, genetic factors, which result in altered expression or enzymatic function of key steroidogenic proteins or their upstream regulators, might further exacerbate variations in the conversion of DHEA to testosterone...
July 2015: Nature Reviews. Endocrinology
Alessandra Gennari, Mauro Costa, Matteo Puntoni, Laura Paleari, Andrea De Censi, Maria Pia Sormani, Nicoletta Provinciali, Paolo Bruzzi
The increasing practice of hormonal infertility treatments (HITs) raised concerns about their effects on breast cancer (BC) risk. Available evidence reported conflicting results. The aim of this study was to assess the potential association between HITs and BC risk. The literature was searched through November 2014. Eligible studies included cohort studies reporting BC incidence in women undergone HITs. Data were analyzed with standard meta-analytic techniques. Subgroup analyses were performed by type of intervention (IVF vs...
April 2015: Breast Cancer Research and Treatment
Soudabeh Sabetian, Mohd Shahir Shamsir, Mohammed Abu Naser
Elucidation of the sperm-egg interaction at the molecular level is one of the unresolved problems in sexual reproduction, and understanding the molecular mechanism is crucial in solving problems in infertility and failed in vitro fertilization (IVF). Many molecular interactions in the form of protein-protein interactions (PPIs) mediate the sperm-egg membrane interaction. Due to the complexity of the problem such as difficulties in analyzing in vivo membrane PPIs, many efforts have failed to comprehensively elucidate the fusion mechanism and the molecular interactions that mediate sperm-egg membrane fusion...
December 2014: Systems Biology in Reproductive Medicine
Mary Ellen Pavone, Jennifer Hirshfeld-Cytron, Angela K Lawson, Kristin Smith, Ralph Kazer, Susan Klock
CONTEXT: Cancer survival has improved significantly and maintaining fertility is both a major concern and an important factor for the quality of life in cancer patients. AIMS: To explore differences in oocyte stimulation for fertility preservation (FP) patients based on cancer diagnosis. SETTINGS AND DEIGN: Between 2005 and 2011, 109 patients elected to pursue FP at a single institution. MATERIALS AND METHOD: In vitro fertilization (IVF) outcome variables between four cancer diagnostic groups (breast, gynecologic, lymphoma/leukemia and other) and age-matched male factor or tubal factor infertility IVF control group were compared...
April 2014: Journal of Human Reproductive Sciences
Marte Myhre Reigstad, Inger Kristin Larsen, Tor Åge Myklebust, Trude Eid Robsahm, Nan Birgitte Oldereid, Anne Katerine Omland, Siri Vangen, Louise Annette Brinton, Ritsa Storeng
Despite increasing numbers of women availing themselves of assisted reproductive technology (ART), effects on cancer risk remain unresolved. Given hormonal exposures, breast cancer risk is of particular concern. The aim of this study is to investigate breast cancer risk amongst women giving birth following ART as compared to that amongst women who gave birth without ART. Data on all women who gave birth in Norway with or without ART, between 1984 and 2010 were obtained from the Medical Birth Registry of Norway (MBRN)...
March 1, 2015: International Journal of Cancer. Journal International du Cancer
Dror Meirow, Hila Raanani, Ettie Maman, Shani Paluch-Shimon, Moran Shapira, Yoram Cohen, Irena Kuchuk, Ariel Hourvitz, Jacob Levron, Michal Mozer-Mendel, Masha Brengauz, Hana Biderman, Daphna Manela, Rephael Catane, Jehoshua Dor, Raoul Orvieto, Bella Kaufman
OBJECTIVE: To evaluate the safety and efficacy of tamoxifen co-administration during conventional controlled ovarian hyperstimulation (COH) protocols for a fertility-preservation IVF cycle in breast cancer patients. DESIGN: Two groups: retrospective descriptive cohort study and prospective study. SETTING: Breast cancer oncology and fertility-preservation centers in a tertiary hospital. PATIENT(S): Two groups of breast cancer patients: premenopausal patients treated with adjuvant tamoxifen; and patients undergoing in vitro fertilization (IVF) for fertility preservation...
August 2014: Fertility and Sterility
F Desvignes, J L Pouly, L Janny, M Canis, S Sanfilippo, J Kanold, G Lebouedec, F Brugnon
OBJECTIVES: Ovarian Tissue Cryopreservation (OTC) is a very promising approach of fertility preservation for women and young patients who have to follow gonadotoxic treatments (chemotherapy, radiotherapy…). The aim of this study was to analyse the indications and the outcomes of the patients who had OTC in our center during the last 17 years. PATIENTS AND METHODS: The study is retrospective. Forty-six patients, who underwent OTC in the Laboratory of Reproductive Biology of the University Hospital of Clermont-Ferrand, between January 1997 and December 2009, were included...
May 2014: Gynécologie, Obstétrique & Fertilité
Shlomit Riskin-Mashiah
Breast cancer is the most common cancer in women in Israel and throughout the world. It is the leading cause of death from cancer in women. The cause of breast cancer is unknown; however gynecological history and hormonal factors have a major impact on the risk to develop breast cancer. Infertility affects 15-20% of couples in developed countries and most of them will need fertility treatment. The variety of fertility treatments and their use has been widespread during the last 50 years and especially since the introduction of in vitro fertilization...
October 2013: Harefuah
Miro Kasum, Lidija Beketić-Orešković, Parvin F Peddi, Slavko Orešković, Rebecca H Johnson
In many countries of the developed world, there is an increasing trend toward delay in childbearing from 30 to 40 years of age for various reasons. This is unfortunately concordant with an increasing incidence of breast cancer in women who have not yet completed their family. The current choice for premenopausal women with breast cancer is adjuvant therapy which includes cytotoxic chemotherapy, ovarian ablation (by surgery, irradiation, or chemical ovarian suppression), anti-estrogen therapy, or any combination of these...
February 2014: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Claudia Bozza, Fabio Puglisi, Matteo Lambertini, Etin-Osa Osa, Massimo Manno, Lucia Del Mastro
Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Müllerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation...
February 2014: Endocrine-related Cancer
Theodoros N Sergentanis, Andreas-Antonios Diamantaras, Christina Perlepe, Prodromos Kanavidis, Alkistis Skalkidou, Eleni Th Petridou
BACKGROUND: The effects of controlled ovarian hyperstimulation (COH) for IVF in terms of breast cancer risk remain controversial, despite the hormone-dependent nature of the latter. METHODS: Eligible studies up to 15 February 2013 were identified and pooled effect estimates for relative risk (RR) were calculated separately for the investigations using the general population and those using infertile women, as a reference group. Fixed- or random-effects models were implemented and subgroup analyses were performed, as appropriate...
January 2014: Human Reproduction Update
Giuseppe Lo Russo, Gian Paolo Spinelli, Silverio Tomao, Belardino Rossi, Luigi Frati, Pierluigi Benedetti Panici, Patrizia Vici, Giovanni Codacci Pisanelli, Federica Tomao
In recent years, there has been an increase in the diagnosis of infertility. In industrialized countries, approximately 15% of couples experience this problem today, with a negative impact on quality of life. For this reason, assisted reproductive technologies and other treatments, finalized to overcome infertility, have become very common in clinical practice. For a long time, different ovulation-inducing drugs have been used for ovarian follicle stimulation, either as independent therapies or treatments used during in vitro fertilization cycles...
February 2013: Expert Review of Anticancer Therapy
Louise A Brinton, Britton Trabert, Varda Shalev, Eitan Lunenfeld, Tal Sella, Gabriel Chodick
OBJECTIVE: To assess long-term cancer risks associated with in vitro fertilization (IVF). DESIGN: Record-linkage study. SETTING: Health maintenance organization in Israel. PATIENT(S): A total of 87,403 women evaluated and/or treated for infertility on or after September 25, 1994, who were followed for cancer development through June 22, 2011: 522 breast, 41 endometrial, 45 ovarian, 311 in situ cervical, and 32 invasive cervical cancers were identified...
April 2013: Fertility and Sterility
A Andrey Urias, B Martinez De Tejada, S Monnier, I Streuli, O Irion
Intraoperative radiotherapy (IORT) has been shown to be as effective as traditional radiotherapy in the management of early stage breast cancer. IORT is performed in a single session and consists in a single irradiation in the tumorectomy cavity. Medically assisted procreation does not seem to favor neither gynecological nor non-gynecological cancers. Nevertheless medically assisted procreation technique ICSI (intracytoplasmic sperm injection) is associated with an increased risk of birth defect. This is not the case of IVF (in vitro fertilization)...
January 9, 2013: Revue Médicale Suisse
L Angulo, C Perreau, N Lakhdari, R Uzbekov, P Papillier, S Freret, V Cadoret, C Guyader-Joly, D Royere, C Ponsart, S Uzbekova, R Dalbies-Tran
STUDY QUESTION: Does BCAR4 have a role in mammalian embryo development? SUMMARY ANSWER: Expression, localization and functional data support that BCAR4 is a maternal-effect protein in non-rodent mammals. WHAT IS KNOWN ALREADY: BCAR4 was previously identified as an oocyte-specific gene in cattle, and as a marker of certain breast tumors in humans. STUDY DESIGN, SIZE, DURATION: Human oocytes were obtained from patients undergoing IVF, but had failed to mature after ovarian stimulation...
February 2013: Human Reproduction
Juan A Garcia-Velasco
The use of aromatase inhibitors (AIs) in IVF patients remains controversial. AIs can be considered for ovulation induction for IVF in women who are normal and poor responders, are at risk of ovarian hyperstimulation syndrome or thrombosis, who have endometriosis, and/or are undergoing fertility preservation procedures as a result of estrogen-dependent cancers, primarily breast and endometrial cancers. Although the biologic plausibility of the capacity of AIs in IVF patients is promising, results should be interpreted with caution, because the efficacy of AIs needs to be proven in randomized trials...
December 2012: Fertility and Sterility
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"